Hospital
Stillwater Medical Center Authority
Stillwater Medical Center Authority was paid $15.75M by Medicaid between Jan 2018 and Nov 2024, across 101 billing codes. Its largest line is 99284, emergency room visit (serious) — 26% of everything it billed.
33Billing provider infoSTILLWATER MEDICAL CENTER AUTHORITY
STILLWATER, OK 74074
STILLWATER, OK 74074
33aNPI1164494027assigned 02/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.75M
24GClaims165,146
24DCodes billed101
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Oklahoma
Rank by total paid#9 of 75
Median peer was paid$3.66M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,362 | $1.55M | |
| 2019 | 15,565 | $1.88M | |
| 2020 | 13,535 | $1.55M | |
| 2021 | 22,475 | $2.25M | |
| 2022 | 38,017 | $3.25M | |
| 2023 | 40,667 | $3.74M | |
| 2024incomplete | 20,525 | $1.52M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 17,417 | 17,150 | $4.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 10,979 | 10,830 | $3.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 14,309 | 14,190 | $2.31M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 11% | 2,597 | 2,594 | $1.79M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 8.6% | 392 | 392 | $1.36M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.9% | 9,192 | 8,968 | $1.09M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 6,422 | 6,227 | $257K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 2,407 | 2,392 | $226K |
| 80053 | Comprehensive metabolic panel | <1% | 10,430 | 9,927 | $98K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,272 | 13,564 | $91K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,463 | 2,418 | $88K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,279 | 8,941 | $79K |
89 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,327 | $65K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 380 | $63K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,982 | $59K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 692 | $56K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 351 | $48K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 115 | $47K |
| 80050 | General health panel | <1% | 1,565 | $47K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 744 | $44K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,471 | $44K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 301 | $40K |
| 62323 | <1% | 85 | $35K | |
| 42830 | <1% | 14 | $32K | |
| 81001 | <1% | 10,200 | $32K | |
| 87088 | <1% | 3,297 | $23K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 431 | $21K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,025 | $21K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,043 | $18K |
| 86710 | <1% | 1,198 | $15K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,092 | $14K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 161 | $14K |
| 80081 | <1% | 195 | $12K | |
| 80061 | Lipid panel | <1% | 974 | $11K |
| 42821 | <1% | 13 | $10K | |
| 83690 | <1% | 1,824 | $10K | |
| 83655 | <1% | 843 | $9K | |
| 72110 | <1% | 287 | $9K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 282 | $8K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 282 | $8K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 34 | $7K |
| 87081 | <1% | 1,012 | $7K | |
| 81025 | <1% | 1,012 | $7K | |
| 84484 | <1% | 669 | $7K | |
| 20610 | <1% | 53 | $7K | |
| 84439 | <1% | 943 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 722 | $6K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 389 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 393 | $5K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 65 | $5K |
| 82947 | <1% | 1,379 | $5K | |
| 87581 | <1% | 150 | $4K | |
| 87486 | <1% | 150 | $4K | |
| 62321 | <1% | 13 | $4K | |
| 84703 | <1% | 639 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 261 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 404 | $3K |
| 83735 | <1% | 380 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,578 | $2K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 25 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,985 | $1K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 27 | $1K |
| 83880 | <1% | 37 | $1K | |
| 85014 | <1% | 520 | $1K | |
| 72050 | <1% | 29 | $1K | |
| 87653 | <1% | 36 | $1K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,042 | $1K |
| 84481 | <1% | 67 | $866.59 | |
| 86803 | <1% | 78 | $862.92 | |
| 86787 | <1% | 78 | $776.21 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 80 | $766.92 |
| 86756 | <1% | 49 | $643.18 | |
| 80306 | <1% | 32 | $472.75 | |
| 81000 | <1% | 131 | $433.18 | |
| 87077 | <1% | 62 | $304.26 | |
| 82728 | <1% | 26 | $303.00 | |
| 72100 | <1% | 12 | $251.60 | |
| 80305 | <1% | 26 | $251.46 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 468 | $235.77 |
| 85027 | <1% | 41 | $234.78 | |
| 83550 | <1% | 25 | $186.48 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12 | $176.40 |
| 83540 | <1% | 25 | $138.00 | |
| 86038 | <1% | 13 | $135.75 | |
| 86140 | <1% | 13 | $59.93 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,013 | $45.75 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,346 | $31.65 |
| 86592 | <1% | 12 | $15.20 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 353 | $8.64 |
| S0028 | Injection, famotidine, 20 mg | <1% | 12 | $6.56 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,172 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 394 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 69 | $0.00 |
| 36000 | 0% | 152 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 98 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 33 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 860 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 75 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 14 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWEBBER, DENISE (CEO)
| Provider | Location | Paid |
|---|---|---|
| Stillwater Medical Center Authority | Stillwater, OK | $13.28M |
| Stillwater Medical Center Authority | Perry, OK | $1.38M |
| Stillwater Medical Center Authority | Blackwell, OK | $275K |
| Stillwater Medical Center Authority | Perry, OK | $113K |
| Stillwater Medical Center Authority | Perry, OK | $111K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.